Effect of budesonide combined with montelukast on lung function and serum levels of IL-6,IL-8 and TNF-αin patients with chronic obstructive pulmonary disease
- VernacularTitle:布地奈德联合孟鲁司特钠对慢性阻塞性肺疾病患者肺功能及血清中IL-6、IL-8和TNF-α的影响
- Author:
Yuying YU
;
Kechong HU
;
Huifang XU
- Publication Type:Journal Article
- Keywords:
budesonide;
montelukast;
COPD;
IL-6;
IL-8;
TNF-α
- From:
Chinese Journal of Biochemical Pharmaceutics
2014;37(7):153-155
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the effect and lung function of the budesonide combined with montelukast for treatment of chronic obstructive pulmonary disease(COPD)and the effect on serum IL-6,IL-8 and TNF-α.Methods 120 patients with COPD in our hospital from April 2012 to December 2013 were randomly divided into observation group and control group (n =60 ).Observation group was given budesonide combined with montelukast on the basis of general routine treatment and control group was given budesonide on the basis of general routine treatment.The lung function and the level of IL-6、IL-8 and TNF-αin serum were detected berore and after treatment.Results The efficacy in observation group was significantly better than that in control group(P<0.05).The forced vital capacity(FVC),forced expiratory volume in one second(FEV1),maximal mid expiratory flow(MMEF),and peak expiratory flow(PEF)in the observation group were significantly higher than those in the control group(P<0.05 ).In addition, after treatment the levels of IL-6,IL-8 and TNF-αexpression in serum of the observation group and control group were significantly lower than before treatment,but the levels of the observation group after treatment was significantly lower than the control group,the difference were statistically significant (P<0.05).Conclusion The efficacy of the budesonide combined with montelukast for treatment of COPD is exact by reducing cytokine release, controling airway inflammation to improve the lung function.It is worthy to be popularized.
